

Form PTO-1449

Docket Number (Optional)

4075US

Application Number

09/332,803

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

JUL 23 1999

(Use several sheets if necessary)

Applicant **V gels t al.**Filing Date **June 14, 1999**Group Art Unit **To be****assigned 1634****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
<i>02</i>	WO 97/00326	01/03/97	PCT				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

RECEIVED**AUG 10 1999****TECH CENTER 1600/2000**

EXAMINER

David S. S. S.

DATE CONSIDERED

1/24/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 4075US	Application Number To be assigned 09/332803
	Applicant Ronald Vogels; Abraham Bout	
	Filing Date June 14, 1999	Group Art Unit To be assigned 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>RL</i>	5,378,618	01/03/95	Sternberg et al.	X	X	X
<i>RL</i>	5,545,522	08/13/96	Van Gelder et al.			
<i>RL</i>	5,652,224	07/29/97	Wilson et al.			
<i>RL</i>	5,670,488	09/23/97	Gregory et al.			
<i>RL</i>	5,707,618	01/13/98	Armentano et al.			
<i>RL</i>	5,753,500	05/19/98	Shenk et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
<i>RL</i>	WO 94/12649	06/09/94	PCT	—	—	X	
<i>RL</i>	WO 94/23582	10/27/94	PCT	—	—	X	
<i>RL</i>	WO 94/26914	11/24/94	PCT	—	—	X	
<i>RL</i>	WO 94/28152	12/08/94	PCT	—	—	X	
<i>RL</i>	WO 95/00655	01/05/95	PCT	—	—	X	
<i>RL</i>	95201611.1	06/15/95	EP	—	—	X	
<i>RL</i>	WO 95/02697	01/26/95	PCT	—	—	X	
<i>RL</i>	95201728.3	06/26/95	EP	—	—	X	
<i>RL</i>	WO 95/27071	10/12/95	PCT	—	—	X	
<i>RL</i>	WO 96/16676	06/06/96	PCT	—	—	X	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

<i>RL</i>	Amalfitano et al., "Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors", <u>Proc. Natl. Acad. Sci. USA</u> , 93:3352-3356, April 1996.
<i>RL</i>	Amalfitano et al., "Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy", <u>Gene Therapy</u> , 4:258-263, 1997.
<i>RL</i>	Armentano et al., "Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion", <u>Human Gene Therapy</u> , 6:1343-1353, October 1995.
<i>RL</i>	Blase et al., "Vectors in Cancer therapy: how will they deliver?", <u>Cancer Gene Therapy</u> , Vol. 2, No. 4, 1995, pp. 291-297.
<i>RL</i>	Bout et al., "In vivo adenovirus-mediated transfer of human CFTR cDNA to Rhesus monkey airway epithelium: efficacy, toxicity and safety", <u>Gene Therapy</u> 1, pp. 385-394, 1994.
<i>RL</i>	Bout et al., "Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium", <u>Human Gene Therapy</u> , 5:3-10, 1994.

EXAMINER <i>David Snyg</i>	DATE CONSIDERED <i>1/26/01</i>
-------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 4075US	Application Number To be assigned 09/332803
	Applicant Ronald Vogels; Abraham Bout	
	Filing Date June 14, 1999	Group Art Unit To be assigned 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
<i>PC</i>	WO 96/18418	06/20/96	PCT			X	
<i>CC</i>	WO 96/33280	10/24/96	PCT			X	
<i>CC</i>	WO 96/40955	12/19/96	PCT			X	
<i>CC</i>	WO 97/00326	01/03/97	PCT			X	
<i>PC</i>	WO 97/00947	01/09/97	PCT			X	
<i>CC</i>	WO 97/04119	02/06/97	PCT			X	
<i>CC</i>	WO 97/05255	02/13/97	PCT			X	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

<i>CC</i>	Brough et al., "A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4", <u>Journal of Virology</u> , 70(9):6497-6501, September 1996.
<i>CC</i>	Brough et al., "Stable Cell Lines for Complementation of Adenovirus Early Regions E1, E2A and E4; Abstract Book CSH Conference On Gene Therapy, 42, 1996.
<i>CC</i>	Brough et al., "Construction, Characterization, and Utilization of Cell Lines Which Inducibly Express the Adenovirus DNA-Binding Protein", <u>Virology</u> , 190:624-634, 1992.
<i>CC</i>	Caravokyri et al., "Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5", <u>Journal of Virology</u> , 69(11):6627-6633, November 1995.
<i>CC</i>	Fallaux et al., "Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors", <u>Human Gene Therapy</u> , 7:215-222, 1996.
<i>CC</i>	Fallaux et al., "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses", <u>Human Gene Therapy</u> , 9:1909-1917, September 1, 1998.
<i>CC</i>	Fisher et al., "Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis", <u>Virology</u> , 217:11-22, 1996.
<i>CC</i>	Gao et al., "Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy", <u>Journal of Virology</u> , 70(12):8934-8943, December 1996.

EXAMINER <i>David J. J. J.</i>	DATE CONSIDERED <i>1/26/01</i>
-----------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 4075US	Application Number 09/332803 To be assigned 1636
	Applicant Ronald Vogels; Abraham Bout	
	Filing Date Jun 14, 1999	Group Art Unit To be assigned 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO


OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

<i>RL</i>	Gorziglia et al., "Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy", <u>Journal of Virology</u> , 70(6):4173-4178, June 1996.
<i>RL</i>	Haddada et al., "Adenoviral Interleukin-2 Gene Transfer into P815 Tumor Cells Abrogates Tumorigenicity and Induces Antitumoral Immunity in Mice", <u>Human Gene Therapy</u> , 4:703-711, 1993.
<i>RL</i>	Hardy et al., "Construction of Adenovirus Vectors through Cre-lox Recombination", <u>Journal of Virology</u> , 71(3):1842-1849, March 1997.
<i>RL</i>	Hehir et al., "Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modifications To Prevent Their Occurrence", <u>Journal of Virology</u> , 70(12):8459-8467, December 1996.
<i>RL</i>	Imler et al., "Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors", <u>Gene Therapy</u> , 3:75-84, 1996.
<i>RL</i>	Kornberg, Arthur, "DNA Replication", W.H. Freeman and Company, San Francisco, 8 pages.
<i>RL</i>	Krougliak et al., "Development of Cell Lines Capable of ComPLEMENTING E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants", <u>Human Gene Therapy</u> , 6:1575-1586, December 1995.
<i>RL</i>	Lieber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo", <u>Journal of Virology</u> , 70:8944-8960, December 1996.
<i>RL</i>	Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , 5 pages.
<i>RL</i>	Sabatie et al., "Process Development for the Production of Second Generation Adenovirus Vectors for Gene Transfer in Clinical Protocols", Abstract Book 14th Meeting on Animal Cell Technology, BI-3, 1996.
<i>RL</i>	Schaack et al., "Adenovirus Type 5 Precursor Terminal Protein-Expressing 293 and HeLa Cell Lines", <u>Journal of Virology</u> , 69(7):4079-4085, July 1995.
<i>RL</i>	Vanhaesebroeck et al., <u>Virology</u> , 176(2), pp. 362-368, June 1990.
<i>RL</i>	Vincent et al., "Herpes Simplex Virus Thymidine Kinase Gene Therapy for Rat Malignant Brain Tumors", <u>Human Gene Therapy</u> 7:197-205, January 20, 1996.
<i>RL</i>	Vincent et al., "Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene", <u>J. Neurosurg.</u> , Vol. 85, pp. 648-654, 1996.
<i>RL</i>	Wang et al., "A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions", <u>Gene Therapy</u> , 2:775-783, 1995.
<i>RL</i>	Yeh et al., "Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit", <u>Journal of Virology</u> , 70(1):559-565, January 1996.
<i>RL</i>	Zhou et al., "Development of a ComPLEMENTING Cell Line and a System for Construction of Adenovirus Vectors with E1 and E2a Deleted", <u>Journal of Virology</u> , 70(11):7030-7038, October 1996.

EXAMINER <i>David Myers</i>	DATE CONSIDERED <i>1/24/01</i>
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Fale Corp (2-92)

Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number (Optional) 4075US	Application Number 09/332,803
	Applicant Fallaux et al.	
	Filing Date June 14, 1999	Group Art Unit 1636 To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JK</i>	4,405,712	09/20/83	Vande Woude et al.	<div style="writing-mode: vertical-rl; transform: rotate(180deg);">RECEIVED MAR 10 1999 TO 1700 MAIL ROOM 4</div>		
<i>JK</i>	4,497,796	02/05/85	Salser et al.			
<i>JK</i>	4,727,028	02/23/88	Santerre et al.			
<i>JK</i>	4,740,463	04/26/88	Weinberg et al.			
<i>JK</i>	5,190,931	03/02/93	Inouye			
<i>JK</i>	5,208,149	05/04/93	Inouye			
<i>JK</i>	5,518,913	05/21/96	Massie et al.			
<i>JK</i>	5,837,511	11/17/98	Falck-Pedersen et al.			
<i>JK</i>	5,994,106	11/30/99	Kovesdi et al.			
<i>JK</i>	5,994,128	11/30/99	Fallaux et al.			
<i>JK</i>	6,033,908	03/07/00	Bout et al.			
<i>JK</i>	6,040,174	03/21/00	Imler et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
<i>JK</i>	2,053,187	04/11/93	Canada	—	—		
<i>JK</i>	WO 94/28152	12/08/94	PCT	—	—		
<i>JK</i>	2,007,664	01/20/95	France	—	—		
<i>JK</i>	WO 95/02697	01/26/95	PCT	—	—		
<i>JK</i>	CA 2117668	09/10/95	Canada	—	—		
<i>JK</i>	AU-A-28533/95	03/21/96	Australia	—	—		

EXAMINER <i>David Tuzo</i>	DATE CONSIDERED <i>1/26/01</i>
-------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* No English translation or English abstract or explanation of relevance of the reference.